The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**AALL0232**: The AALL0232 study for children with high-risk B-precursor acute lymphoblastic leukemia (ALL) compared high-dose (HD) methotrexate (MTX) with leucovorin rescue to Capizzi escalating MTX plus PEG asparaginase given during the interim maintenance phase of treatment. The results, which were presented at the ASCO 2011 Plenary Session, showed that 5-year event-free survival (EFS) for patients randomized to receive HD-MTX was significantly higher than for patients receiving Capizzi MTX (82 + 3.4% versus 75.4 + 3.6%, p=0.006). These results establish a new standard of care for children with high-risk B-precursor ALL.

**NCIC-MA.20**: MA.20 evaluated the addition of regional nodal irradiation (RNI) to whole breast irradiation (WBI) following breast conserving surgery (BCS) in women with high risk node-negative or node-positive breast cancer treated with BCS and adjuvant chemotherapy and/or endocrine therapy. A protocol specified interim analysis of relapse patterns, survival, and toxicity at 5 years demonstrated that additional RNI reduces the risk of loco-regional and distant recurrence and improves DFS with a trend in improved OS. The results of this study support the use of regional nodal irradiation in addition to WBI in women with early stage breast cancer at increased risk of recurrence.
Cooperative Group Abstracts

Breast Cancer

**ACOSOG**


[http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8af32ba1-289f-4f43-b9d3-9e44806821e1&cKey=bae82f3c-c765-4fc6-8c98-6d497d470f4f&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8af32ba1-289f-4f43-b9d3-9e44806821e1&cKey=bae82f3c-c765-4fc6-8c98-6d497d470f4f&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C})

Protocol(s): ACOSOG-Z1031

**ACRIN**


[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84250](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84250)

Protocol(s): 8029


[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84074](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84074)

Protocol(s): ACRIN-6691

**ECOG**


[http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf](http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf)

Protocol(s): E2Z04


Other Participant(s): CALGB

Protocol(s): E5103

Simpson JF, Sander ME, Page DL: Diagnostic Accuracy of Ductal Carcinoma In Situ: Results of Eastern Cooperative Oncology Trial 5194. United States and Canadian Academy of Pathology, San Antonio, TX, Feb 2011. Abst. 256.


Protocol(s): E5194
NCCTG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77800
Protocol(s): N0735

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79057
Protocol(s): N9831

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81832
Protocol(s): N9831

NCIC Clinical Trials Group

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84625
Protocol(s): NCIC-MA.27B

http://origin.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82573
Protocol(s): NCIC-MA.32

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78090
Protocol(s): NCIC-MA.27
http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=79126
Protocol(s): NCIC-MA.20

http://www.asco.org/ASCov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81808
Protocol(s): NCIC-MA.21, NCIC-MA.27

NSABP

http://abstract.asco.org/AbstView_102_76755.html
Protocol(s): NSABP-P-1

http://abstract.asco.org/AbstView_102_83942.html
Protocol(s): NSABP-B-40

http://abstract.asco.org/AbstView_102_78110.html
Protocol(s): NSABP-B-14

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=100&abstractID=60277
Protocol(s): NSABP-B-39

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=42a4e4de-967e-47ba-9e1-e70c514a626c&cKey=102e3f1e-c54d-4194-a6e7-45b1992dde3c&mKey=%7b507D311A-B6EC-436A-BD67-6D14ED39622C%7d

Protocol(s): NSABP-P-1, NSABP-P-2

SWOG


http://abstract.asco.org/AbstView_102_74054.html

Other Participant(s): ECOG

Protocol(s): S0221

Gonzalez-Angulo AM, Barlow WE, Gralow JR, Mercic-Bernstam F, Hayes DF, Moinpour CM, Ramsey SD, Schott A, Sparks D, Albain KS, Hortobagyi GN: SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. J Clin Oncol 2011; 29(suppl): Abst. TPS104.

http://abstract.asco.org/AbstView_102_76547.html

Protocol(s): S1007


http://abstract.asco.org/AbstView_102_82693.html

Protocol(s): S1007


http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=73b6a59d-cfe5-4b41-b6cc-bbc9f6572757&cKey=59dd466-c618-420e-9bb8-11bad423d3e89&mKey=%7b507D311A-B6EC-436A-BD67-6D14ED39622C%7d

Protocol(s): S0221
CNS Cancer

COG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80733
Protocol(s): ADVL0819

NCCTG

Anderson SK, Lafky JM, Carrero XW, Kimlinger TK, Halling TM, Kumar S, Flynn PJ, Gross HM, Jaeckle KA, Buckner JC, Galanis E: Single nucleotides polymorphism (SNPs) and circulating endothelial cells (CECs) in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). J Clin Oncol 2011; 29(suppl): Abst. 2019.
http://origin.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83751
Protocol(s): N0776

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80655
Protocol(s): N0572

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84868
Protocol(s): N057K

RTOG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83983
Protocol(s): RTOG-0525

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79423
Protocol(s): RTOG-0525
Protocol(s): RTOG-0525

Protocol(s): RTOG-0525

Gastrointestinal Cancer

ACRIN

Protocol(s): ACRIN-6690

CALGB

Other Participant(s): NCCTG
Protocol(s): CALGB-80101

Protocol(s): CALGB-80303

Protocol(s): C80405, C89803
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77737
Protocol(s): C9581

NCCTG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80710
Protocol(s): N0147

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83472
Protocol(s): NCCTG-78-48-51, NCCTG-79-41-51, NCCTG-83-41-51

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82287
Protocol(s): N994C

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79465
Protocol(s): N0147, N9741, N9841

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82873
Protocol(s): N9741

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80808
Protocol(s): N0147
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84051
Protocol(s): N0745

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71370
Protocol(s): N064B

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82619
Protocol(s): N064B

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83471
Protocol(s): N054C

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b3725d8a-a800-4cc4-b970-0930f769ec50&cKey=5ce30236-5aaa-4e72-91be-6a073b1fa120&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}
Protocol(s): N054C

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84660
Protocol(s): N0147

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84534
Protocol(s): N0441
http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=83516
Protocol(s): N0441

NSABP

http://abstract.asco.org/AbstView_102_78086.html
Protocol(s): NSABP-C-08

http://abstract.asco.org/AbstView_102_78884.html
Other Participant(s): NCCTG
Protocol(s): N0441, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

http://abstract.asco.org/AbstView_102_79417.html
Other Participant(s): NCCTG
Protocol(s): N0441, NSABP-C-01, NSABP-C-02, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

http://abstract.asco.org/AbstView_102_76910.html
Other Participant(s): NCCTG
Protocol(s): NSABP-R-04

RTOG

http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=103&abstractID=70410
Protocol(s): RTOG-98-11
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70410
Protocol(s): RTOG-98-11

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71101
Protocol(s): RTOG-0529

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70619
Protocol(s): RTOG-97-04

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84182
Protocol(s): RTOG-97-04

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80887
Protocol(s): RTOG-0132

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31098
Protocol(s): RTOG-0247
SWOG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71402
Protocol(s): S0356

http://abstract.asco.org/AbstView_102_82045.html
Protocol(s): S0356

http://abstract.asco.org/AbstView_102_84455.html
Protocol(s): INT-0144

Genitourinary Cancer

COG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82480
Protocol(s): Q9401

Protocol(s): AREN0321

ECOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81790
Protocol(s): E2805
Protocol(s): E3803

NCIC Clinical Trials Group

Other Participant(s): SWOG
Protocol(s): JPR.7

Other Participant(s): COG, SWOG
Protocol(s): JPR.7

RTOG

Protocol(s): RTOG-85-31, RTOG-86-10, RTOG-92-02, RTOG-94-13

SWOG

Gynecologic Cancer

GOG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74500
Other Participant(s): ACRIN
Protocol(s): GOG-0233

Protocol(s): GOG-0218

Protocol(s): GOG-0170D

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74267
Protocol(s): GOG-9921

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74397
Protocol(s): GOG-0248

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79146
Protocol(s): GOG-0233
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=85086
Protocol(s): GOG-111

Protocol(s): GOG-LAP2

Protocol(s): GOG-0205

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84396
Protocol(s): GOG-9918

Protocol(s): GOG-0182

Protocol(s): GOG-0227E

Head and Neck Cancer

ECOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83432
Protocol(s): E2303

NCI-Sponsored Groups Meetings Report
Summer 2011
RTOG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79086
Protocol(s): RTOG-0522

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77744
Protocol(s): RTOG-0615

Leukemia, Myelodysplasia, and Transplantation

COG

Protocol(s): AAML0531

Protocol(s): AALL0631

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84168
Protocol(s): CCG-2961

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=85112
Protocol(s): POG-9905
Protocol(s): AAML0531

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83893  
Protocol(s): AALL0232

Protocol(s): Multiple Trials

Protocol(s): AALL0433

Protocol(s): AALL0232

Protocol(s): CCG-2961

Protocol(s): AALL07P2
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83582
Protocol(s): AALL0232

SWOG

http://abstract.asco.org/AbstView_102_79396.html
Protocol(s): SWOG-9031, SWOG-9126, SWOG-9333, SWOG-9500

Lung Cancer

ACOSOG

http://www.aats.org/annualmeeting/Abstracts/2011/55.html
Protocol(s): ACOSOG-Z4032

ACRIN

http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf
Protocol(s): ACRIN-6654

CALGB

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78904
Protocol(s): CALGB-30002, CALGB-30206, CALGB-39808

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80550
Protocol(s): CALGB-9633
ECOG

Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano SL, Adjei AA, Schiller J: Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29(suppl): Abst. 7013.

http://abstract.asco.org/AbstView_102_81235.html

Other Participant(s): CALGB, NCCTG, SWOG
Protocol(s): E1505

NCCTG


http://abstract.asco.org/AbstView_102_81867.html

Other Participant(s): SWOG
Protocol(s): Multiple Trials, N0424


http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84434
Protocol(s): N0626


http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79299

NCIC Clinical Trials Group


http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83123
Other Participant(s): CALGB, ECOG, NCCTG, RTOG, SWOG
Protocol(s): Multiple Trials
RTOG

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77622
Protocol(s): RTOG-0212, RTOG-0214

SWOG

http://abstract.asco.org/AbstView_102_83663.html
Protocol(s): S0429

Lymphoma and Plasma Cell Disorders

CALGB

http://annonc.oxfordjournals.org/content/22/suppl_4/iv106.short
Protocol(s): CALGB-50103

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=47551
Protocol(s): CALGB-50501

http://annonc.oxfordjournals.org/content/22/suppl_4/iv220.short
Protocol(s): CALGB-50501

ECOG

http://annonc.oxfordjournals.org/content/22/suppl_4/iv86.short
Protocol(s): E1499
http://annonc.oxfordjournals.org/content/22/suppl_4/iv148.full.pdf+html
Other Participant(s): SWOG
Protocol(s): E4494

**SWOG**

http://annonc.oxfordjournals.org/content/22/suppl_4/iv119.short
Protocol(s): S0350

http://abstract.asco.org/AbstView_102_77208.html
Other Participant(s): ECOG
Protocol(s): S9704

**Melanoma/Skin Cancers**

**ECOG**

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77947
Protocol(s): E1697

**NCCTG**

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77235
Protocol(s): N0775
Other Cancer

**COG**

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76045](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76045)
Protocol(s): ADVL0413, ADVL0613, ADVL0714, ADVL0815

[http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf](http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf) 
Protocol(s): ANUR0631

[http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf](http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf) 
Protocol(s): ANUR0631

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83577](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83577)
Protocol(s): ADVL0813

[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81126](http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81126) 
Protocol(s): ADVL0815

[http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf](http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf) 
Protocol(s): ANUR0631

[http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf](http://ons.metapress.com/content/0v354m827hn6g548/fulltext.pdf) 
Protocol(s): ANUR0631
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=75114
Protocol(s): A3973

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e23b3dc0-d3c6-449e-97e6-bdd4ac7a9416&cKey=7e42f201-b87c-44e1-9e08-f6689236d5b&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}
Protocol(s): ANBL00B1, ANBL06B1

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=73830
Protocol(s): ADVL0916

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1e9d7bf3-0e72-41b4-9497-4b6c2571e994&cKey=5ec25177-fba1-442c-a4db-855a8371639d&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}
Protocol(s): POG-9047

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b6998c29-6e3f-495f-8544-698de95f915b&cKey=9e9c498f-2e6e-4673-83d2-be1752f02835&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}
Protocol(s): ANBL00B1, ANBL06B1

ECOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81011
Protocol(s): E2Z02
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77126  
Protocol(s): E2Z02

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79783  
Protocol(s): E4Z02

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82706  
Protocol(s): E2Z02

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80175  
Protocol(s): E2Z02

NCCTG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=85098  
Protocol(s): Multiple Trials

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77649  
Protocol(s): NCCTG-N08C7

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76731  
Protocol(s): NCCTG-N08C1
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84505
Protocol(s): N0147

RTOG

http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf
Protocol(s): Multiple Trials

http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf
Protocol(s): Multiple Trials

SWOG

Anderson K, Hartline J, Harris-Talley J: Study transition from local in-person follow-up to centralized follow-up by mail. American Society of Preventive Oncology Annual Meeting (ASPO), Las Vegas, NV, Mar 2011.
Protocol(s): S0000

http://ajrccm.atsjournals.org/cgi/content/citation/183/1_MeetingAbstracts/A6419
Protocol(s): S0000

Protocol(s): S0000

http://www.sctweb.org/docs/mtg2011/SCT%20pre-program%2018March.pdf
Protocol(s): S0000

Protocol(s): S0000
Sarcoma/Bone and Soft Tissue Cancers

COG

http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=84838

Protocol(s): AEWS07P1

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2734&sKey=41cc4bb-aa2-42a9-88a6-564221f1d892&cKey=70177852-8ea8-41a5-bfd2-14d894fa0fba&mKey=507D311A-BDEC-436A-BD67-6D14ED39622C

Protocol(s): AEWS0031

http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=77259

Protocol(s): ARST0331

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=83906

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=102&abstractID=83703
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81085

**DCTD and DCP Activities**

*Educational*


Zujewski, JA (DCTD/CTEP): Clinical Trial Design and Methodology. ASCO International Clinical Trials Workshop, Cairo, Egypt, Jan 2011.

*Other*


Zujewski, JA (DCTD/CTEP): Regulatory Issues - International perspective. ASCO International Clinical Trials Workshop, Cairo, Egypt, Jan 2011.

Zujewski, JA (DCTD/CTEP): Coordinated meeting on next generation trials of HER-2 positive breast cancer with the goal of addressing key questions regarding the resistance to HER2 targeting, discussing HER2-targeted drugs (including new agents), discussing other drugable targets in HER2-positive breast cancer, and recommending directions for future clinical trials in the treatment of HER2-positive breast cancer. Breast Cancer Steering Committee, Clinical Trials Planning Meeting, Rockville, MD, May 2011.

*Scientific*


Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.